Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study
Completed
- Conditions
- Congenital Bleeding DisorderCongenital FXIII Deficiency
- Interventions
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT01862367
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Aberdeen, United Kingdom
Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 323
- Registration Number
- NCT01850615
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Novo mesto, Slovenia
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 833
- Registration Number
- NCT01849289
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Vinnitsa, Ukraine
Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderCongenital FXIII DeficiencyHealthy
- Interventions
- Drug: placebo
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT01847989
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Berkshire, United Kingdom
Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers
Phase 1
Completed
- Conditions
- Congenital FXIII DeficiencyCongenital Bleeding DisorderHealthy
- Interventions
- Drug: placebo
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01848002
An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01846312
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- Drug: placebo
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1398
- Registration Number
- NCT01836523
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 362
- Registration Number
- NCT01835431
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Madrid, Spain
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1290
- Registration Number
- NCT01831765
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
Completed
- Conditions
- Haemophilia A With InhibitorsHaemophilia B With InhibitorsCongenital Bleeding Disorder
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT01830712
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath